Early observations and pilot data that first suggested a new direction
Despite high-intensity statin therapy, many patients with established cardiovascular disease remained at significant residual risk. The discovery of PCSK9 — a protein that degrades LDL receptors — opened a new therapeutic avenue. Monoclonal antibodies targeting PCSK9 (evolocumab, alirocumab) demonstrated dramatic LDL reductions of 50-60% on top of statin therapy in phase 2 trials, achieving LDL levels previously thought unattainable.
Proof
Landmark RCTs and pivotal trials that established the evidence base
FOURIER (2017) enrolled 27,564 patients with atherosclerotic cardiovascular disease on statin therapy and randomised them to evolocumab or placebo. Evolocumab reduced LDL by 59% and the primary cardiovascular endpoint by 15%. ODYSSEY OUTCOMES (2018) tested alirocumab in 18,924 acute coronary syndrome patients, showing a 15% reduction in MACE and a larger 29% reduction in those with baseline LDL ≥100 mg/dL. These trials proved that further LDL lowering beyond statin-achievable levels translates to cardiovascular benefit with no lower LDL threshold identified.
Follow-up studies, subgroup analyses, and real-world validation
The development of inclisiran — a small interfering RNA (siRNA) that silences PCSK9 production — offered a new delivery paradigm. Rather than biweekly or monthly injections, inclisiran requires only twice-yearly dosing. The ORION-10 and ORION-11 trials demonstrated LDL reductions of approximately 50% with this regimen. The ongoing ORION-4 outcomes trial will determine whether inclisiran's LDL lowering translates to cardiovascular event reduction.
Integration into clinical practice guidelines and recommendations
The ESC/EAS 2019 Dyslipidaemia Guidelines set aggressive LDL targets: <55 mg/dL for very high-risk and <40 mg/dL for very high-risk with recurrent events within 2 years. PCSK9 inhibitors received a Class I, Level A recommendation for patients not achieving targets on maximally tolerated statins plus ezetimibe. This represented the most aggressive lipid-lowering targets in guideline history.
ESC/EAS 2019 Dyslipidaemia Guidelines
Class I, Level A: PCSK9i for very high-risk patients not at LDL target on maximal statin + ezetimibe; target <55 mg/dL
Now
Current standard of care and ongoing research directions
PCSK9 inhibitors are established as third-line lipid-lowering therapy after statins and ezetimibe. Access remains the primary barrier due to cost, though prices have decreased substantially since launch. The ORION-4 outcomes trial for inclisiran is eagerly awaited. Bempedoic acid offers another non-statin option, and oral PCSK9 inhibitors are in development.
What are PCSK9 inhibitors and how do they lower cholesterol?+
PCSK9 inhibitors block the PCSK9 protein, which normally degrades LDL receptors on liver cells. By blocking PCSK9, more LDL receptors remain active on the liver surface to clear LDL cholesterol from the blood. Two monoclonal antibodies (evolocumab, alirocumab) and one siRNA (inclisiran) are approved.
How low should LDL cholesterol go?+
Current ESC/EAS guidelines target LDL <55 mg/dL for very high-risk patients and <40 mg/dL for very high-risk patients with recurrent events. FOURIER and ODYSSEY showed benefit of LDL lowering well below 50 mg/dL with no identified lower threshold of benefit or safety concern.
What is inclisiran and how is it different from other PCSK9 drugs?+
Inclisiran is a small interfering RNA (siRNA) that silences PCSK9 production at the genetic level. Unlike evolocumab and alirocumab (monoclonal antibodies requiring biweekly/monthly injections), inclisiran needs only two injections per year after initial loading doses, potentially improving adherence.
